SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al.Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients.Medicine (Baltimore)2003;82:299308.
  • 2
    Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcon GS, et al.Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004.Arthritis Rheum2013;65:75363.
  • 3
    Alarcon GS, McGwin G Jr, Petri M, Reveille JD, Ramsey-Goldman R, Kimberly RP.Baseline characteristics of a multiethnic lupus cohort: PROFILE.Lupus2002;11:95101.
  • 4
    Wang F, Wang CL, Tan CT, Manivasagar M.Systemic lupus erythematosus in Malaysia: a study of 539 patients and comparison of prevalence and disease expression in different racial and gender groups.Lupus1997;6:24853.
  • 5
    Seligman VA, Lum RF, Olson JL, Li H, Criswell LA.Demographic differences in the development of lupus nephritis: a retrospective analysis.Am J Med2002;112:7269.
  • 6
    Costenbader KH, Desai A, Alarcon GS, Hiraki LT, Shaykevich T, Brookhart MA, et al.Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.Arthritis Rheum2011;63:16818.
  • 7
    Alarcon GS, McGwin G Jr, Petri M, Ramsey-Goldman R, Fessler BJ, Vila LM, et al.Time to renal disease and end-stage renal disease in PROFILE: a multiethnic lupus cohort.PLoS Med2006;3:e396.
  • 8
    Ward MM.Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004.J Rheumatol2009;36:637.
  • 9
    Korbet SM, Schwartz MM, Evans J, Lewis EJ, and the Collaborative Study Group.Severe lupus nephritis: racial differences in presentation and outcome.J Am Soc Nephrol2007;18:24454.
  • 10
    Yazdany J, Panopalis P, Gillis JZ, Schmajuk G, MacLean CH, Wofsy D, et al, for the Systemic Lupus Erythematosus Quality Indicators Project Expert Panels.A quality indicator set for systemic lupus erythematosus.Arthritis Rheum2009;61:3707.
  • 11
    Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al.American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.Arthritis Care Res (Hoboken)2012;64:797808.
  • 12
    Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al.Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis.Ann Rheum Dis2012;71:177182.
  • 13
    Ward MM.Access to care and the incidence of endstage renal disease due to systemic lupus erythematosus.J Rheumatol2010;37:115863.
  • 14
    Chibnik LB, Massarotti EM, Costenbader KH.Identification and validation of lupus nephritis cases using administrative data.Lupus2010;19:7413.
  • 15
    2010 National Committee for Quality Assurance's Quality Compass.2011. URL: http://www.ncqa.org/tabid/60/Default.aspx.
  • 16
    Schmajuk G, Trivedi AN, Solomon DH, Yelin E, Trupin L, Chakravarty EF, et al.Receipt of disease-modifying antirheumatic drugs among patients with rheumatoid arthritis in Medicare managed care plans.JAMA2011;305:4806.
  • 17
    United States Census Bureau. United States Census 2000.2013. URL: http://www.census.gov/main/www/cen2000.html.
  • 18
    Ward MM.Medical insurance, socioeconomic status, and age of onset of endstage renal disease in patients with lupus nephritis.J Rheumatol2007;34:20247.
  • 19
    Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, et al, for the Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics.EULAR recommendations for the management of systemic lupus erythematosus.Ann Rheum Dis2008;67:195205.
  • 20
    Ward MM.Socioeconomic status and the incidence of ESRD.Am J Kidney Dis2008;51:56372.
  • 21
    Frankovich JD, Hsu JJ, Sandborg CI.European ancestry decreases the risk of early onset, severe lupus nephritis in a single center, multiethnic pediatric lupus inception cohort.Lupus2012;21:4219.
  • 22
    Hiraki LT, Feldman CH, Liu J, Alarcon GS, Fischer MA, Winkelmayer WC, et al.Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US Medicaid beneficiary population.Arthritis Rheum2012;64:266976.
  • 23
    Yoon SS, Burt V, Louis T, Carroll MD.Hypertension among adults in the United States, 2009-2010.NCHS Data Brief2012;107:18.
  • 24
    Alarcon GS, McGwin G Jr, Bastian HM, Roseman J, Lisse J, Fessler BJ, et al, for the LUMINA Study Group.Systemic lupus erythematosus in three ethnic groups. VIII. Predictors of early mortality in the LUMINA cohort.Arthritis Rheum2001;45:191202.
  • 25
    Gillis JZ, Yazdany J, Trupin L, Julian L, Panopalis P, Criswell LA, et al.Medicaid and access to care among persons with systemic lupus erythematosus.Arthritis Rheum2007;57:6017.
  • 26
    Henderson L, Masson P, Craig JC, Flanc RS, Roberts MA, Strippoli GF, et al.Treatment for lupus nephritis.Cochrane Database Syst Rev2012;12:CD002922.
  • 27
    A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group.N Engl J Med1991;324:1504.
  • 28
    Alarcon GS, McGwin G, Bertoli AM, Fessler BJ, Calvo-Alen J, Bastian HM, et al.Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L).Ann Rheum Dis2007;66:116872.
  • 29
    Kaiser R, Cleveland CM, Criswell LA.Risk and protective factors for thrombosis in systemic lupus erythematosus: results from a large, multi-ethnic cohort.Ann Rheum Dis2009;68:23841.
  • 30
    Fessler BJ, Alarcon GS, McGwin G Jr, Roseman J, Bastian HM, Friedman AW, et al, for the LUMINA Study Group.Systemic lupus erythematosus in three ethnic groups. XVI. Association of hydroxychloroquine use with reduced risk of damage accrual.Arthritis Rheum2005;52:147380.
  • 31
    Jung H, Bobba R, Su J, Shariati-Sarabi Z, Gladman DD, Urowitz M, et al.The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus.Arthritis Rheum2010;62:8638.
  • 32
    Gansevoort RT, Sluiter WJ, Hemmelder MH, de Zeeuw D, de Jong PE.Antiproteinuric effect of blood-pressure-lowering agents: a meta-analysis of comparative trials.Nephrol Dial Transplant1995;10:196374.
  • 33
    Schmajuk G, Yazdany J, Trupin L, Yelin E.Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus.Arthritis Care Res (Hoboken)2010;62:38692.
  • 34
    Yazdany J, Trupin L, Tonner C, Dudley RA, Zell J, Panopalis P, et al.Quality of care in systemic lupus erythematosus: application of quality measures to understand gaps in care.J Gen Intern Med2012;27:132633.